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Percutaneous coronary intervention in the elderly: are drug-coated balloons the future?  
 
Abstract 
Balloon angioplasty revolutionised percutaneous treatment for coronary artery disease four 
decades ago, but vessel-threatening dissections, elastic recoil and restenosis were major 
drawbacks to an otherwise successful long-lasting intervention. Subsequent advances with 
bare metal stents and then drug eluting stents followed, aiming to mitigate the risks of acute 
vessel closure and restenosis. However, stent implantation often necessitates dual 
antiplatelet therapy for a prolonged period of time, which in itself can lead to adverse 
outcomes, especially in the frail elderly population at higher risk of bleeding. More recently, 
bioabsorbable stents have been implemented in clinical practice enabling earlier intimal 
coverage of the stent and apposition. However, another addition to the armamentarium of 
percutaneous coronary intervention is the use of drug-coated balloons without the need for 
deploying any coronary stents or scaffolds. Drug-coated balloons are semi-compliant balloons 
coated with an antiproliferative agent that is rapidly released on contact with the vessel 
intima exerting an anti-restenotic effect. The absence of a metallic scaffold means that the 
need for antiplatelet therapy can potentially be negated in the longer term if required. In this 
article, we will review the history of percutaneous coronary intervention and the available 
evidence for the appropriate use of drug-coated balloons especially in the elderly population. 
We will conclude this review by demonstrating the potential use of drug-coated balloon 
rather percutaneous stenting through case examples. 
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Background 
Percutaneous coronary intervention began in the 1970s with balloon angioplasty [1]. Bare 
metal stents were soon developed in the mid 80’s to initially treat dissections and acute recoil, 
plus subsequent reduced rates of restenosis whilst introducing new complications such as 
stent restenosis and thrombosis [2].  Drug eluting stents (DES), introduced early in the 
millennium, have significantly reduced the rate of in-stent restenosis but the risk of stent 
thrombosis remains an important complication necessitating prolonged duration of dual 
antiplatelet therapy [3]. More recently, biodegradable scaffolds were developed strategically 
to combine the temporary benefits of a stents with mechanical support and  drug delivery 
with the added advantage of resorption, theoretically allowing a return to  more normal 
vascular structure and function long-term [4]. The drug-coated balloon (DCB) is another 
addition to the therapeutic armamentarium available to the interventional cardiologist, 
combining the benefits of local drug delivery and a shorter duration of dual antiplatelet 
therapy without the complications of stent implantation, in cases where a stent might not be 
necessary or feasible [5]. This might prove invaluable in the modern era characterised by an 
ageing population with multiple comorbidities and high bleeding risk. The treatment of 
coronary artery disease is common in patients over the age of 75 years of age especially within 
the context of acute coronary syndromes. Careful consideration of the treatment strategy for 
acute coronary syndromes in this age group is particularly important in view of their increased 
complexity, complication rate and hospitalisation [6]. In this review, we will briefly discuss the 
history of percutaneous coronary intervention and then focus on the use of drug-coated 
balloons giving particular emphasis on their use in de-novo lesions and in the elderly. 
 
Historical perspective 
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The first balloon angioplasty (BA) was performed by Dr Andreas Gruntzig in 1977 [7] when he 
dilated the left anterior descending artery on a conscious patient. In 1979, the results of the 
first few cases of BA were published and it was estimated that about 10-15% of candidates 
for bypass surgery were suitable for this new technique [1]. It soon became apparent that the 
technique was promising, but not without complications, including acute vessel closure and 
restenosis which affected up to a third of the patients in the first 6 months requiring repeat 
procedures or bypass surgery [2].  
 
Bare metal stents (BMS) were soon developed in an attempt to prevent the acute vessel 
closure or recoil with initial favourable results being first published in 1987 [8]. In 1994, it was 
demonstrated by randomised control trials that elective stent implantation significantly 
reduced the rate of restenosis and need for repeat coronary intervention and thus drove the 
era of elective stent implantation [9,10]. Of particular note however, there was no proven 
prognostic benefit in routine elective stent implantation for patients with stable angina. Use 
of BMS rapidly expanded over the next few years. It resolved problems such as acute vessel 
closure due to dissections and mitigated the issues of acute recoil and constrictive 
remodelling linked to BA but this was at the expense of increased risk of (sub)acute 
thrombosis and in-stent restenosis caused by in-stent neo-intimal hyperplasia and activation 
of vascular and smooth muscle cells [11].  
 
In the early 2000s drug eluting stents (DES) were developed to combine the benefit of a 
mechanical stent scaffold with the local delivery of an anti-proliferative drug to inhibit in-stent 
neo-intimal proliferation. They had demonstrably lower rates of in-stent restenosis compared 
to BMS and their use rapidly proliferated through the cardiology community [11]. Despite DES 
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exhibiting a reduced rate of in-stent restenosis compared with BMS, the risk of stent 
thrombosis still remained, with the added requirement for an extended period of dual 
antiplatelet therapy for the first 12 months and antiplatelet monotherapy thereafter, which 
in turn increases the bleeding risk especially in the elderly [12,13].  
Thus coronary artery stents were developed to treat some of the early complications 
associated with BA and they fulfil this role both acutely (dissection, vessel recoil) or within the 
first few months post-implantation (restenosis). Whilst the main benefits of their use are seen 
in the first few months post-implantation the presence of the permanent metallic scaffolding 
and the need for longer dual antiplatelet therapy can be associated with an adverse bleeding 
profile and prognosis in the longer term. Therefore, biodegradable scaffolds were soon 
developed which would allow the vessel to return to a more physiological state after 
complete resorption with an anticipated benefit that this could allow earlier discontinuation 
of dual antiplatelet therapy when compared to DES; a benefit not fully supported by clinical 
studies [4,14,15] 
 
Nonetheless, all available stenting options involve a “foreign” implanted scaffold albeit for a 
short period of time, which necessitates a period of dual antiplatelet therapy commonly 
varying from one month to one year. Despite the associated increase in bleeding risk, the 
majority of patients tend to tolerate antiplatelet therapy well in trial data  [16,17]. However, 
for patients with hypertension, renal failure, with prior history of peptic ulcer or increased 
age who can have significant bleeding risk [18], even short term dual antiplatelet therapy may 
convey an extremely risky bleeding profile that outweighs the potential benefit of stent 
implantation.  In addition, for certain patients it may become necessary to stop dual 
antiplatelet therapy following implantation of a DES unpredictably such as those diagnosed 
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with neoplasia requiring biopsy or urgent surgery [19]. Therefore, although the percutaneous 
options of metallic scaffolding have evolved and improved through the years including 
transition from BMS to DES and biodegradable scaffolds, the real question is whether the 
same effect of opening the stenosed vessel without the need of any metallic/ biodegradable 
scaffolding is achievable.  Drug-coated balloons (DCB) were developed and now approved in 
Europe in an attempt to mitigate some of the disadvantages of stent implantation such as 
bleeding risk from prolonged dual antiplatelet therapy and stent thrombosis, whilst in the 
USA they have only received Food and Drug Administration (FDA) approval for peripheral non-
coronary interventions at present [20].  
 
Drug-coated balloon 
Using a DCB facilitates delivery of an anti-proliferative drug to the vessel wall without 
implantation of a stent [20]. It comprises a semi-compliant angioplasty balloon coated with 
the anti-proliferative drug and an excipient, an inert carrier molecule that facilitates drug 
transfer and absorption to the vessel wall [21]. Adequate lesion preparation is essential which 
creates microdissections in the vessel wall and allows better uptake of the drug [3]. The 
balloon is then inflated for 30-60 seconds and the drug absorbed into the vessel wall in a 
homogenous manner. Currently the vast majority of DCBs available use the anti-proliferative 
drug paclitaxel although more recently others using sirolimus have also become available in 
Europe. It is the anti-proliferative agent that binds to the β subunit of tubulin, arresting the 
microtubule function and inhibiting cell division. Its lipophilicity and ability to concentrate to 
the arterial wall make it an optimal agent for DCB [22]. There is a relative paucity in the 
guidance available recommending the duration of antiplatelet therapy in patients with DCB 
especially in patients with stable disease undergoing coronary intervention. For acute 
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coronary syndrome patients the need for dual antiplatelet therapy is mandated as part of the 
management [23] for the acute event. However, in DCB-trials dual antiplatelet use was 
variable ranging from 1-12 months. Reassuringly, in most of the trials the duration of dual 
antiplatelet therapy was short at 1-3 months without an increase in the rate of Major Adverse 
Cardiac Events (MACE) when compared to trials with longer duration of dual antiplatelet 
therapy [5]. Therefore, dual antiplatelet therapy for 1 month following DCB implantation for 
stable coronary artery disease has been recommended by an expert group [24]. We will next 
review the evidence of DCB in various scenarios and conclude by addressing the specific use 
of DCB in the elderly. In this article, the terms DCB and drug-eluting balloon (DEB) are used 
interchangeably.  
 
Drug-coated balloons in in-stent restenosis 
The PEPCAD II trial compared the SeQuent Please DCB with the Taxus DES for the treatment 
of in-stent restenosis (ISR). At 6 month follow-up the DCB group had significantly less in-stent 
late lumen loss (LLL) while at 12 month follow-up there was no significant difference in MACE 
making DEB treatment a safe and efficacious alternative option for ISR [25]. These results 
were confirmed by the ISAR-DESIRE 3 trial in 2013 and the PEPDAC China ISR trial in 2014. The 
ISAR-DESIRE 3 trial was a three-arm randomised controlled trial comparing DEB vs DES 
(Paclitaxel) vs. BA. At 7 month follow-up DEB was non-inferior to DES in terms of diameter 
stenosis and both groups were superior to BA alone [26]. The PEPCAD China ISR trial 
compared the SeQuent Please DCB with Taxus DES for the treatment of ISR in DES. At 9 month 
follow-up the DCB group was non-inferior to DES group in terms of LLL and at 12 month 
follow-up the two groups had similar clinical events [27]. Despite these encouraging results 
when DCB was compared with Paclitaxel-DES, the RIBS IV trial in 2015 showed that 
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Everolimus-DES was superior to SeQuent Please DCB for treatment of ISR of DES. At 1 year 
follow-up the DES group had significantly larger minimal lumen diameter, larger net luminal 
gain, lower diameter stenosis and fewer adverse clinical outcomes mainly driven by less need 
for target vessel revascularisation (TVR). The authors took great care in terms of pre-dilatation 
and avoiding geographical mismatch [28]. However, a rather generous <50% stenosis was 
considered as an acceptable result post PCI in the DCB arm, whereas in most centres <30% 
stenosis would be considered acceptable.  
At present, DCB remain a treatment option of ISR according to the European Society of 
Cardiology guidelines on myocardial revascularisation [29] and also appear to be cost-
effective compared to DES for restenosis treatment [30].  
 
Drug-coated balloons in small vessel disease 
In an increasingly diverse arena with multiple therapeutic options available, small calibre 
vessels were studied as a likely indication where drug-coated balloons may offer the most 
reasonable solution. Small calibre vessels, one of the strongest predictors of restenosis even 
in the era of DES, allow DCB to utilise their unique properties [31]. PEPCAD I was the first 
single-arm study that evaluated a DCB (Sequent Please) in small calibre vessels (vessel 
diameter of 2.25-2.8mm) in patients with an average age of 68 years. The DCB-only group 
achieved very good angiographic and clinical results which were maintained at 12 and 36 
months follow-up. Patients who needed BMS-bailout had worse results in terms of late lumen 
loss (LLL), restenosis and target lesion revascularisation (TLR) and worse clinical outcomes at 
12 and 36 month follow up. These were attributed possibly to geographical mismatch as most 
of the restenosis occurred at stent edges [32,33].  
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The PICCOLETO study compared the DIOR-PCB with Taxus DES in small vessels (<2.75mm). 
This study included elderly patients with the average age of the patients being 67 and 68 
years, respectively in the two groups and followed up for 9 months. The study had to be 
stopped prematurely due to clearly superior clinical outcomes of the Taxus group mainly 
driven by TLRs [34]. However, it is difficult to draw definitive conclusions from this study as 
the first generation DCB used (DIOR placlitaxel-coated balloon) achieved low tissue drug 
dosage.  In addition lesion preparation was inadequate with a pre-dilation rate of only 25% 
and low inflation pressures [3,33].  
 
The BELLO study was the first study that showed positive findings comparing the In.Pact 
Falcon DCB to Taxus DES in small vessels (vessel diameter <2.8mm). The average age was 64 
and 66 years of age respectively. The primary outcome of in-stent (in-balloon) late loss was 
significantly less in the DCB group compared to the DES group. There were similar rates of 
revascularisation and restenosis. It has to be noted that the pre-dilation rate before DEB was 
96.8% and that in cases of BMS-bailout avoidance of geographical mismatch was considered. 
However, in the subgroup of patients who needed BMS-bailout (20%) the LLL was significantly 
increased and similar to the DES group. [3,35].  
 
Drug-eluting balloons in bifurcation lesions 
Coronary bifurcation lesions account for approximately 20% of all percutaneous coronary 
interventions as they continue to provide a significant challenge, being associated with lower 
procedural success rates and higher rates of adverse cardiac events, even in experienced 
centres in the era of DES. 
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The DEBIUT was a three-arm trial designed to assess the efficacy of DEB pre-dilatation of the 
side branch (SB) in bifurcation lesions. Groups A and B were treated with a BMS in the main 
branch (MB) after pre-dilatation of both MB and SB with DIOR-I DEB and regular balloon 
respectively. Group C was treated with a paclitaxel DES at the MB after dilatation with a 
regular balloon of the MB and SB. Final kissing regular balloon dilatation was mandatory in all 
groups. The DES group was significantly better than both other groups while the DEB group 
did not show angiographic superiority compared to BMS group. The authors made the 
comment that tissue drug delivery with the DIOR-I is significantly less compared to Sequent 
Please even though the loading doses are comparable, and thus opened the gate for future 
studies in that area [36].  
 
The BABILON trial assessed provisional BMS T-stenting technique with pre-dilatation of both 
SB and MB with SeQuent Please DEB versus Xience V DES T-stenting technique with pre-
dilatation with regular balloons. Final kissing balloon dilatation was at operator’s discretion 
and there was a significant difference between the two groups with the BMS/DEB group 
having significantly less final kissing. The average age of patients was 64 years of age. The 
main advantage of DEB is negating the need for any stent placement and therefore this was 
not assessed in this study as the DEB group always had BMS associated it.  As the BMS is 
known to be inferior to DES with regards to in-stent restenosis, it was therefore no surprise 
that the DES group had significantly less in-stent restenosis while the BMS/DEB group had 
significantly more TLR but the difference was due to main branch TLR. Importantly, there were 
no significant angiographic differences in the SB. Additionally, the two groups did not have 
any significant differences in MACE. The authors concluded that although an everolimus-DES 
provisional strategy appeared to be the preferred strategy the use of DEB in the SB appeared 
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safe, and therefore further studies using DES in the MB and SB vs DES in the MB and DEB in 
the SB were warranted. [37] 
 
Another important study in intervention of bifurcation lesions with T stenting was by Herrador 
and colleagues who compared 50 patients who had a DES (Taxus Liberte) in the MB and DEB 
in the SB (Sequent Please) against 50 patients with a DES in the MB and conventional 
ballooning in the SB with both groups having kissing balloon post dilation [38]. The average 
age in this study was 62 years old. There was no difference in clinical MACE between the two 
groups but there was a trend towards less SB in the DEB group (7% vs 20%, p=0.08) suggesting 
that DEB is a safe and possibly more effective strategy.  
 
The BIOLUX-1 study was the first multicentre study to assess the safety and efficacy of an 
everolimus-DES (Xience V/Xience Prime) in the MB with a Paclitaxel-DEB (Pantera LUX) in the 
SB for bifurcation lesions. The average age was 66 years old. The MB was pre-dilated first, the 
SB was treated with a DEB and then the MB was treated with a DES. Only one case received 
pre-dilatation of the SB with a regular balloon before the DEB and even though the protocol 
mandated final kissing balloon inflation, this only occurred in 37.2% of cases. Furthermore, a 
core angiographic laboratory assessment showed that only 11 out of 35 patients had true 
bifurcation lesions. A separate assessment of the patients with true bifurcation lesions 
showed that the low LLL was maintained and the complications rate was low. Despite of the 
limitations of this small pilot study, the authors concluded that the combination of DES in the 
MB with DEB in the SB is safe and effective [39].   
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The PEPCAD BIF trial evaluated the use of SeQuent Please DCB vs. BA in bifurcation lesions 
(with no proximal main branch disease though). The average age of the patients was 67 years 
of age. At 9-month follow up the DCB group had less restenosis rate and LLL. The authors 
concluded that DCB treatment is a sound option for bifurcation lesions with proximal main 
branch disease as long as there is only class A or B dissection and recoil <30% [40].  
 
Drug-coated balloons in diabetes 
It has long been demonstrated that patients with diabetes have increased risk of in-stent 
restenosis with vessel calibre, length of stent and lower BMI being the most important 
predictors of restenosis [41]. The PEPCAD IV trial compared the use of SeQuent Please DCB 
followed by cobalt-chromium stent vs. DES (Taxus Liberte) in patients with diabetes. The 
average age of patients was 62 and 58 years of age respectively. Even though it was 
recommended by the protocol, only 31% of patients in the DCB group underwent pre-
dilatation. However, at 9-month follow up there was no significant difference in the clinical 
or angiographic outcomes. The LLL, TLR and MACE were similar [42]. Although this study 
showed some promising results for the DCB group, there was no arm including DCB without 
stenting which could have shown even better results.  
 
Drug-coated balloons in STEMI 
With increasing experience of the DCB in coronary work, soon trials utilising them in acute 
myocardial infarction started to become available. The DEB-AMI trial was the first one to 
evaluate a DEB in the context of STEMI. It was a three-arm randomised control trial comparing 
BMS alone vs. BMS together with DEB vs. DES alone. It is important to note that the devices 
used were a modern cobalt chromium BMS, the DIOR DEB (first generation) and the TAXUS 
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Liberte DES, and no randomised group utilised DEB monotherapy. The average age of patients 
was 60 years for the first two groups and 56 years for the third group. Even though it was 
mandated by the protocol, only 60% of the patients in the DEB group underwent pre-
dilatation. The DIOR DEB group failed to show superiority compared to BMS while the DES 
group had significantly better angiographic and clinical results. The DEB group had fewer mal-
apposed and uncovered struts compared to the DES group but more than BMS group as 
assessed by optical coherence tomography. Therefore even though there was no established 
clinical benefit with DEB compared to BMS, it was demonstrated that there was a drug effect. 
The authors felt that these data could be explained by reduced bioavailability of paclitaxel to 
the lesion either due to the excipient in the DEB or due to the fact that only 60% of patients 
underwent pre-dilatation. Indeed, subgroup analysis showed that the patients with pre-
dilatation had significant less LLL compared to the patients without pre-dilatation [43]. It is 
important to realise that there was a subsequent 4th non-randomised arm of DEB-AMI trial 
showed that the DEB-only arm had similar outcomes compared to BMS or BMS with DEB but 
inferior to DES. The authors concluded the DEB-only could be considered as a treatment 
option during primary percutaneous coronary intervention (PPCI) in patients with 
contraindication to DES [44].   
A more recent study from Amsterdam [45] also confirmed the safety and feasibility of a DCB 
in PPCI with the option of bailout stenting if required. A total of 100 patients presenting with 
a STEMI were included and 59 managed with DCB alone, while 41 patients required additional 
stenting indicating that DCB use as main treatment in this setting could be justified. Similar 
data from our unit with 253 patients treated with DCB in PPCI showed that stent bail out was 
only necessary for 9% of the patients, of which only 0.8% were for acute vessel closure. In 
addition at 12 month follow up TLR was 3.3% and mortality 6.3% supporting the existing data 
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that a DCB initial approach in PPCI is possible and indicating that further research is warranted 
in this field [46].  
 
Drug-coated balloons in elderly 
Drug-coated balloons have been evaluated in various groups of patients. However, to the best 
of our knowledge, there is no randomised control trial specifically targeting the elderly 
population. In addition, as it can be noticed from the average age of the patients included in 
the studies mentioned above, the elderly have not been studied as a dedicated group; a 
subject that merits further discussion. According to the British Cardiovascular Intervention 
Society audit in 2015, 22551 coronary interventions took place in patients aged between 71-
80 years old, 9422 PCIs in patients between 81-90 years old and 559 PCIs in patients >90 years 
old [47]. These data demonstrate that elderly patients undergo large numbers of 
percutaneous coronary interventions in routine clinical practice even through they only have 
a very small representation in clinical trials.  With an increasingly ageing population the 
prevalence of acute coronary syndromes in the elderly will continue to increase affecting both 
sexes [48].  This is an important group particularly as older patients are at a higher risk of 
bleeding even with single antiplatelet agents [49,50]. In addition, elderly patients frequently 
have indications for anticoagulation, such as atrial fibrillation which becomes more frequent 
with advancing age. Therefore, an option that might allow a short-term use of dual 
antiplatelet therapy and then further allow complete discontinuation of the one remaining 
antiplatelet medication if signs of bleeding appear would be pioneering, as it can allow 
clinicians to protect patients during the immediate acute event and then tailor subsequent 
antiplatelet therapy in a personalised fashion. To date, there is only one prospective study in 
elderly with small vessel coronary artery disease acquired from the SeQuent Please Small 
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Vessel ‘Paclitaxel-Coated Balloon Only’ Registry [51]. The older group (>75 years old) had 
significantly higher incidence of hypertension, renal insufficiency, atrial fibrillation and 
calcified lesions. There was no difference in MACE (4.2% vs 6.1%) or TLR (3.9% vs 3%) at 9 
months between the younger and older group. According to the authors, this result appears 
similar to the everolimus-eluting stent TLR rate of 5.1% at 1 year from the SPIRIT Small Vessel 
Trial.  
The appeal of DCB in the elderly population is mainly driven by the shortened period of dual 
antiplatelet therapy, therefore conveying a lesser bleeding risk, which is of particular 
importance in the presence of multiple comorbidities. A DCB approach can also enable 
discontinuation of all antiplatelets if clinically needed without predisposing patients to stent 
thrombosis as in the case with stents.  Unfortunately, there is often a general perception that 
upper gastrointestinal bleeding is mainly non-disabling with low mortality rate, however 
whilst this might well be true for the majority of younger patients, the elderly patients do get 
more frequent and more significant, including lethal, bleeding. A recent prospective 
population-based cohort study in patients after a vascular event (Myocardial Infarction (MI), 
Transient Ischaemic Attach (TIA) and Stroke) treated with aspirin without proton pump 
inhibitor confirmed that elderly patients (>75 years old) have higher risk of major bleeding 
with significant risk of disabling or fatal upper gastrointestinal bleeding [50], indicating that a 
decision to prescribe even single long-term aspirin monotherapy in the elderly should be 
carefully considered. Therefore, treatment options such as DCB with their reduced duration 
for dual antiplatelet therapy might become very useful and relevant in the elderly patient 
with multiple comorbidities and high bleeding risk. However, at present there is little evidence 
to formulate a strong recommendation for DCB use as a first approach, with stenting as a 
secondary option if required, in the elderly for both elective and acute situations.  New 
16 
 
randomised studies comparing DCB with DES should be undertaken in the elderly population 
both in the acute and elective setting to establish the evidence on which to base further 
treatment options. Such studies should offer medium to long term follow up data especially 
as the benefit of DCB might be seen at later stages with reduced bleeding risk and mortality 
due to reduced antiplatelet use. On the balance of the current evidence we feel that an initial 
approach to use DCB in elderly patients with high risk of bleeding is justified, and if this 
approach fails then a metallic stent, either BMS or DES depending on the particular individual 
and clinical history, can be considered.  
 
In the following section we will describe some cases managed by DCB alone, indicating their 
potential use in clinical practice. 
 
Clinical cases where DCB was preferentially used 
Case 1 
DCB in a patient at high risk of bleeding requiring anticoagulation for atrial fibrillation. 
A 72 year old man with prior cardiac surgery (mitral valve repair), permanent atrial fibrillation 
and hypertension presented with increasing stable angina that interfered with his quality of 
life. Diagnostic angiography (Panel A) showed critical mid left anterior descending (LAD) 
artery stenosis of a calcified vessel with TIMI 1 flow. Following discussion about the possible 
therapeutic options rotablation was initially undertaken in the LAD and treated with a 2.5 x 
20 mm SeQuent Please DCB with an excellent angiographic result (Panel B). He remained on 
a novel anticoagulant and antiplatelet monotherapy both in the acute and longer term period. 
At 6 months routine angiography revealed patent vessel (Panel C).  
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Figure 1 
 
Figure 1 Coronary angiograpghy in a patient with stable angina showing significant calcific 
LAD disease (panel A, arrow) which was treated with DCB showing immediate (panel B) result 
and result at six months (panel C).  
 
The patient remained completely asymptomatic when last seen 9 months following the 
intervention. This case highlights the benefit of DCB use in a patient with extensive cardiac 
history where repeat surgical revascularisation was not indicated and where a DES was likely 
to require dual antiplatelet therapy for 12 months in addition to oral anticoagulation, and 
then antiplatelet monotherapy long term alongside anticoagulation without the option of 
stopping the monotherapy if there was any significant concern about bleeding risk. However, 
with DCB the antiplatelet therapy could be discontinued if necessary.  
 
Case 2 
DCB use in a patient at high bleeding risk. 
A 74 year old lady with stable angina underwent diagnostic angiography which showed 
significant circumflex disease (Panel A). She had a history of bleeding ulcers and the lesion 
was pre dilated with a semi-compliant balloon and final drug delivery was achieved with a 3.0 
x 15 mm SeQuent Please DCB with a satisfactory result (Panel B).  Dual anti platelets were 
continued for a month followed by monotherapy thereafter.  
At 42 months repeat angiography was undertaken when she presented with atypical chest 
pain which showed an excellent long lasting result from the DCB (panel C). This case highlights 
the excellent long term outcome that can be achieved with DCB in a patient at high risk of 
bleeding.  
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Figure 2 
 
 
Figure 2 A patient with severe circumflex lesion (panel A, arrow) was treated with DCB in view 
of bleeding history showing good result post DCB (panel B) and at 42 months (panel C).  
 
Case 3 
DCB use in a patient with an ST Elevation Myocardial Infarction 
A 78 year old man presented with acute chest pain and electrocardiography confirmed an 
anterior STEMI. Emergency angiography revealed an occluded LAD which was treated 
successfully with thrombus aspiration and pre dilatation with a semi-compliant balloon 
followed by a final 4 x 20 mm SeQuent Please DCB. Panels A, B and C show pre, during and 
immediate post PCI angiography images respectively. Panel D shows follow up angiography 
at 3 months when he returned for staged intervention for by-stander circumflex disease. Dual 
antiplatelet therapy was continued for a year (for acute myocardial infarction) but it would 
have been possible to discontinue one of the antiplatelets at one month if the need arose.  
 
Figure 3 
 
Figure 3 shows an occluded LAD (panel A, arrow) which was treated with DCB with good result 
(panel B during procedure, panel C post-procedure) which was maintained 3 months later 
when the patient returned for a staged procedure to his by-stander circumflex disease. 
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This case highlights that a DCB can provide a solid strategy even in patients presenting with 
AMI to reduce the period needed for dual antiplatelet therapy if required (for example 
bleeding risk or scheduled surgery) and the angiographic outcome can be excellent.  
 
Conclusion 
There has been an amazing advance in the field of percutaneous coronary intervention since 
its introduction in the 1970s. Using evidence-based therapy we have moved from balloon 
angioplasty, to bare metal stents, and then to drug eluting stents and biodegradable scaffolds. 
However, in the modern era of the more complex and potentially frail patients, it is important 
for the interventional cardiologist to have a variety of treatment options available in their 
armamentarium. Drug-coated balloons are this latest development trying to find its place and 
role in an ever developing field. It is evident from the studies reviewed that there is not a 
uniform class effect among the drug-coated balloons as all individual components of the 
device can affect its performance. The results so far are encouraging such that the indications 
for drug-coated balloon use will continue to grow beyond in-stent restenosis and small vessel 
disease even though at present studies are in general small with some conflicting results. The 
elderly is a large group of patients encountered in daily clinical practice, yet unfortunately 
remain underrepresented in trials. They comprise a complex group of patients with multiple 
comorbidities and increased risk of bleeding risk who are also at a higher risk of acute 
coronary syndromes. Drug-coated balloons could provide a useful tool to allow the 
cardiologist to achieve very good clinical results in dilating culprit vessels without the need of 
longer term dual antiplatelet therapy, however further studies are urgently required in this 
group of patients to allow appropriate classification and solid guideline recommendation for 
their use. 
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List of abbreviations 
 
AMI Acute Myocardial Infarction 
BA Balloon angioplasty 
BMS Bare Metal Stent 
DCB Drug-coated balloon 
DEB Drug Eluting Balloon 
DES Drug Eluting Stent 
FDA Food and Drug Administration 
ISR In-stent restenosis 
MACE Major Adverse Cardiac Events  
MB Main branch 
MI Myocardial Infarction 
LLL Late lumen loss 
PCI Percutaneous Coronary Intervention 
PPCI Primary Percutaneous Coronary Intervention 
SB Side branch 
STEMI ST Elevation Myocardial Infarction 
TIA Transient Ischaemic Attack 
TLR Target lesion revascularisation 
TVR Target vessel revascularisation 
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